BPC-157 Compounding Pharmacy: 503A vs 503B for This Peptide

Print or save as PDFOpens the printable question sheet and your print dialog. No sign-up.

Is BPC-157 on FDA's pharmacy bulk substances list?

No. FDA's page listing nominated bulk substances for state-licensed pharmacies and physicians (updated May 14, 2026) places BPC-157 in none of its three categories [1]. That includes category 1, the group FDA says it generally will not act against compounders for when conditions are met, so that discretion does not extend to BPC-157 [1].

The peptide does appear elsewhere on FDA's site. The page on bulk substances that may present significant safety risks (content dated 04/22/2026) lists BPC-157 in a 'nominated but withdrawn' table rather than the active category 2 table [7]. It had been in category 2 from September 2023 until April 22, 2026, and it moved because the groups that nominated it withdrew their nominations, not because FDA concluded it was safe [7][4].

FDA's stated concerns remain on that page: compounded BPC-157 'may pose risk for immunogenicity for certain routes of administration' and may have problems with peptide-related impurities and characterization of the active ingredient, and FDA 'has identified no, or only limited, safety-related information for the proposed routes of administration' [7].

Is BPC-157 on the bulk substances list for outsourcing facilities?

No. BPC-157 is absent from FDA's list of bulk drug substances for outsourcing facilities (updated March 21, 2025) [2]. An outsourcing facility is a large compounder registered with FDA, and the draft HHS policy described below does not name this type of facility [3][4].

Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [2][3][4].

What the October 2026 draft policy says

BPC-157 is a synthetic 15-amino-acid peptide, and FDA treats the free base and the acetate salt as two different bulk substances [5]. The draft policy names BPC-157 acetate only [4].

On October 28, 2026, HHS filed a notice announcing a draft enforcement-discretion policy covering six peptides, BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500, scheduled for Federal Register publication on October 30, 2026, with public comments open for two weeks after publication [3][4].

HHS says it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician that compounds with a listed peptide while FDA's list is developed through rulemaking, if the policy's conditions are met [3][4].

The notice is explicit that this is neither approval nor a listing. It 'does not establish any rights for any person and is not binding on HHS or the public,' and HHS may revisit the policy, for instance if a safety signal or a product quality issue appears [3][4].

The conditions the draft attaches to BPC-157

For BPC-157, the draft policy lists these conditions [4]:

• BPC-157 acetate, not the free base
• Subcutaneous, intramuscular, oral or topical forms; nasal, rectal and intravenous are not listed
• A single active ingredient
• Bulk substance from an FDA-registered manufacturer, with a valid certificate of analysis meeting a peptide testing standard
• A label reading 'This is a compounded drug product. Not for resale.'
• A patient-specific prescription
• Serious adverse events and quality problems reported to FDA MedWatch
• Only an FDA 510(k)-cleared syringe as a co-packaged device
• For oral forms, documentation of adequate bioavailability

Why FDA's own reviewers recommended against listing it

In a July 2026 briefing, FDA reviewers proposed that BPC-157 not be added to the pharmacy bulks list, citing that it is not well characterized chemically, that there is little information on its safety and immunogenicity, that the evidence is insufficient for ulcerative colitis, the use FDA evaluated, and that several approved drugs already treat ulcerative colitis [5].

On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee voted in favor of adding BPC-157 to the pharmacy bulks list, against the staff recommendation. The recommendation is not binding, and BPC-157 has not been added to the list; adding it requires formal rulemaking, meaning a proposed rule, public comment and a final rule [6][4].

What the safety record looks like

FDA's review found insufficient clinical safety information to characterize BPC-157's safety profile, and no human studies of the peptide given by mouth, by subcutaneous injection, by nasal spray or on the skin [5]. Its search of the adverse-event database through December 4, 2025 turned up three reports, all for injectable product: injection-site redness and swelling lasting nine days in a patient who also used compounded thymosin, shortness of breath leading to an emergency room visit, and widespread skin and gum darkening that recurred on re-exposure to a BPC-157 plus TB-500 'research' product. FDA said it cannot tell whether BPC-157 caused them [5].

In animal toxicity work, 28-day intramuscular studies showed shortened clotting time (aPTT) in rats and prolonged aPTT in dogs, plus raised ALT, glucose and triglyceride levels; longer studies and cancer-risk studies were not available [5].

A 2026 systematic review of human studies in orthopaedic and regenerative use found three studies with 30 patients total, all of poor methodological quality, with certainty of evidence rated very low; the reviewers concluded BPC-157 should not be used clinically outside ethically approved, regulated, high-quality trials [8].

What the draft path looks like in practice

The draft describes a narrow, conditional path for state-licensed pharmacies, federal facilities and licensed physicians: acetate only, four routes, a single ingredient, a documented bulk source, a patient-specific prescription and MedWatch reporting [4]. It is a non-binding statement of enforcement intent that can change [3]. FDA found no human studies for the subcutaneous, oral and topical routes the draft names [5].